Options Explored for MM That Relapses After BCMA CAR T Therapy

WEDNESDAY, Nov. 9, 2022 -- Patients with multiple myeloma that relapses after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy can potentially be treated with multiple lines of salvage therapy, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news